

別添 5

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
H. Maeda	Recollections of 45 years in research: From protein chemistry to polymeric drugs to the EPR effect in cancer therapy.	Seth. D. Grahame	Science Education in a Rapidly Changing World	Nova Science Publishers	New York, USA	2011	1-30
H. Maeda	Enhanced permeability and retention effect in relation to tumor targeting.	F. Kratz, P. Senter, H. Steinhagen	Drug Delivery in Oncology. From Basic Research to Cancer Therapy	Wiley-VCH Verlag GmbH & Co.	Weinheim, Germany	2011	Vol. 1, 65-84
K. Hochdörffer, G. DiStefano, L. Fiume, H. Maeda, F. Kratz	Liver tumor targeting.	F. Kratz, P. Senter, H. Steinhagen	Drug Delivery in Oncology. From Basic Research to Cancer Therapy	Wiley-VCH Verlag GmbH & Co.	Weinheim, Germany	2011	Vol.3, 1519-68
H. Nakamura, H. Maeda	Nanomedicine and cancer drug delivery based on the EPR effect and EPR augmentation.	I. Uchegbu	Fundamentals in Pharmaceutical Nanosciences	Springer	New York, USA	2013	401-27

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
H. Maeda, Y. Matsumura	History and impact of EPR effect for the nanomedicine drug developments in cancer chemotherapy.	Adv. Drug Delivery Reviews	63	129-30	2011
J. Fang, H. Nakamura, and H. Maeda	EPR effect: the unique characteristics of tumor blood vessels for drug delivery, factors involved, its limitation and augmentation.	Adv. Drug Delivery Reviews	63	136-51	2011
H. Nakamura, J. Fang, B. Gahininath, K. Tsukigawa, H. Maeda	Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; Unique intracellular disintegration of SMA micelles.	J. Control. Release	155	367-75	2011

G.Y. Bharate, J. Fang, H. Nakamura, H. Qin, S. Shinkai, and H. Maeda	4-Amino-6- hydroxypyrazolo [3,4-d] pyrimidine (AHPP) conjugated PEG micelles: Water soluble polymeric xanthine oxidase inhibitor.	J. Drug. Targeting	19	954-66	2011
N. Larson, K. Greish, H. Bauer, H. Maeda, H. Ghandehari	Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.	Int'l. J. Pharmaceutics	420	111-7	2011
J. Fang, H. Qin, T. Seki, H. Nakamura, K. Tsukigawa, H. Maeda	Therapeutic potential of pegylated hemin for ROS-related diseases via induction of heme oxygenase-1: results from a rat hepaticischemia/reperfusion injury model.	J. Pharmacol. Exp. Ther.	339	779-89	2011
H. Nakamura, J. Fang, H. Maeda	Protective Role of D-Amino Acid Oxidase Against Bacterial Infection.	Infection and Immunity	80	1546-53	2012
H. Herrmann, M. Kneidinger, S. Cerny-Reiterer, T. Rülicke, M. Willmann, K.V. Gleixner, K. Blatt, G. Hörmann, B. Peter, P. Samorapoompichit, W. Pickl, G. Y. Bharate, M. Mayerhofer, W. R. Sperr, H. Maeda, P. Valent	The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on CD34 ⁺ /CD38 ⁺ and CD34 ⁺ /CD38 ⁻ AML progenitor cells.	Current Cancer Drug Targets	12 (1)	51-63	2012
H. Maeda	Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.	Proc. Jpn. Academy, Series B.	88	53-71	2012
G. Bharate, H. Nakamura, J. Fang, S. Shinkai, H. Maeda	Styrene-co-maleic Acid (SMA) Telomeric Micelles Encapsulated-Zinc Protoporphyrin (SMA-ZnPP) and Other Drugs: Stability Study.	CRS Newsletter	29	6-7	2012
J. Fang, H. Qin, H. Nakamura, K. Tsukigawa, H. Maeda	Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention (EPR) effect of solid tumor.	Cancer Science	102	535-41	2012

J. Fang, K. Greish, H. Qin, H. Nakamura, M. Takeya, H. Maeda	HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: In vitro and in vivo anticancer effect.	Eur. J. Pharm. Biopharma.	81	540-7	2012
H. Nakamura, J. Fang, T. Mizukami, H. Nunoi, H. Maeda	Pegylated D-amino acid oxidase restores bactericidal activity of neutrophils in chronic granulomatous disease via hypochlorite	Exp. Biol. Med.	237	703-8	2012
Y. Ishima, D. Chen, J. Fang, H. Maeda, A. Minomo, U. Kragh-Hansen, T. Kai, T. Maruyama, M. Otagiri	S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects	Bioconjug. Chem	23	264-71	2012
H. Maeda	Macromolecular therapeutics in cancer treatment: the EPR effect and beyond,	J. Control. Release	164	138-44	2012
前田 浩	EPR効果に基づく腫瘍のターゲッティングと蛍光イメージング	Progress in Drug Delivery System XXI (2012年9月1日開催静岡DDSカンファレンス抄録)		5-12	2012
H. Nakamura, L. Liao, Y. Hitaka, K. Tsukigawa, V. Subr, J. Fang, K. Ulbrich, H. Maeda	Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo.	J. Control. Release	165	191-8	2013
H. Maeda, H. Nakamura, J. Fang	The EPR effect for macromolecular drug delivery to solid tumors: improved tumor uptake, less systemic toxicity, and improved tumor imaging - Review of the vascular permeability of tumors and the EPR effect.	Adv. Drug Deliver. Rev	65	71-9	2013
U. Prabhakar, H. Maeda, R. K. Jain, E. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, D.C. Blakey,	Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology.	Cancer Res.	73	2412-7	2013
S. Yamamoto, Y. Kaneo, H. Maeda	Styrene maleic acid anhydride copolymer (SMA) for the encapsulation of sparingly water-soluble drugs in nanoparticles.	J. Drug Del. Sci. Tech.	23	231-7	2013

H. Maeda	The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.	Cancer Sci.	104	779-89	2013
J. Fang, T. Seki, T. Tetsuya, H. Qin, H. Maeda,	Protection from inflammatory bowel disease and colitis-associated carcinogenesis with 4-vinyl-2, 6-dimethoxyphenol (canolol) via suppression of oxidative stress	Carcinogen.	34	2833-41	2013
J.H. Grossman, S. McNeil [翻訳] H. Maeda	Nanotechnology in Cancer Medicine, Physics Today 65, 38-42 (2012) 「がん治療におけるナノテクノロジー」	パリティ誌、丸善書店			2013 8月号
H. Nakamura, T. Etrych, P. Chytil, M. Ohkubo, J. Fang, K. Ulrich, H. Maeda	Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. - 23 -	J. Control. Release	174	81-7	2014
S. Cerny-Reiterer, R. A. Meyer, H. Herrmann, B. Peter, K. V. Gleixner, G. Stefanzl, E. Hadzijusufovic, W. F. Pickl, W. R. Sperr, J. V. Melo, H. Maeda, U. Jäger, P. Valent	Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.	Oncotarget.			Online Mar.4, 2014
H. Yin, J. Fang, L. Liao, H. Nakamura, and H. Maeda	Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease.	J. Control Release			in press, 2014
H. Maeda	Analysis of the causes of failures in cancer chemotherapy and improvements for tumor-selective drug delivery, therapeutic efficacy, and eliminating adverse effects.	Proc. Jpn. Academy Ser. B			in press, 2014
H. Maeda	Emergence of EPR effect theory and development of clinical applications for cancer therapy.	Therapeutic Delivery (Future Science)			in press, 2014
H. Nakamura, J. Fang, H. Maeda	Macromolecular cancer drug development for next generation drugs based on the EPR effect: challenges and pitfalls	Expert Opinion on Drug Delivery			in press, 2014

H. Nakamura, E. Koziolová, T. Etrych, P. Chytil, J. Fang, K. Ulbrich, H. Maeda	Improved pharmacokinetics and antitumor activity of new dendrimer-derived poly(<i>N</i> -(2-hydroxypropyl) methacrylamide) conjugates of pirarubicin	Eur. J. Pharm. Biopharm.			in press, 2014
Y. Ishima, J. Fang, Ulrich Kragh-Hansen, H. Yin, L. Liao, N. Katayama, H. Watanabe, T. Kai, A. Suenaga, H. Maeda, M. Otagiri, and T. Maruyama	Tuning of Poly- <i>S</i> -Nitrosated Human Serum Albumin as Superior Antitumor Nanomedicine.	J. Pharm. Sci.			in press, 2014
中村 秀明、方 軍、前田 浩	EPR効果に基づくポリマー抗癌剤の腫瘍デリバリー：微小癌の検出・治療を目的としたセラノスティック薬剤の開発	月刊「化学工業」			in press, 2014 6月号
J. Fang, L. Liao, H. Yin, H. Namamura, T. Shin, H. Maeda	nhanced bacterial tumor delivery by modulating the EPR effect, and therapeutic potential of <i>Lactobacillus casei</i>	J. Pharm. Sci.			Submitted, 2014
前田 浩	現今のがん治療薬のかかえる問題	公益財団法人札幌がんセミナー会報 SCSコミュニケーション The Way Forward			in press, 2014